NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its board has initiated a share repurchase plan on Tuesday, April 24th 2018, which authorizes the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 18.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Waters Co. (NYSE:WAT) announced its quarterly earnings results on Wednesday, January, 23rd. The medical instruments supplier reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.23. The medical instruments supplier earned $715 million during the quarter, compared to the consensus estimate of $702.74 million. Waters had a return on equity of 34.18% and a net margin of 24.54%. Waters's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.51 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Waters.

Waters updated its FY19 earnings guidance on Wednesday, January, 23rd. The company provided earnings per share guidance of $9.20-9.45 for the period, compared to the Thomson Reuters consensus estimate of $9.18. Waters also updated its FY 2019 guidance to $9.20-9.45 EPS.

14 brokers have issued 12 month price objectives for Waters' stock. Their predictions range from $177.00 to $260.00. On average, they anticipate Waters' stock price to reach $205.3715 in the next year. This suggests that the stock has a possible downside of 12.8%. View Analyst Price Targets for Waters.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

News stories about WAT stock have trended neutral recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Waters earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Home Depot (HD), Cisco Systems (CSCO), Walmart (WMT), Raytheon (RTN), Mcdonald's (MCD), Honeywell International (HON), Starbucks (SBUX) and Philip Morris International (PM).

Waters' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.36%), Fundsmith LLP (6.51%), Massachusetts Financial Services Co. MA (6.42%), Bank of New York Mellon Corp (5.83%), Baillie Gifford & Co. (3.32%) and Jensen Investment Management Inc. (1.39%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Nomura Asset Management Co. Ltd., Ownership Capital B.V., Bank of New York Mellon Corp, D. E. Shaw & Co. Inc., Fundsmith LLP, Bessemer Group Inc., Mackenzie Financial Corp and Principal Financial Group Inc.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Terrence P Kelly and Thomas P Salice. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Bristol John W & Co. Inc. NY, Massachusetts Financial Services Co. MA, Nordea Investment Management AB, Citigroup Inc., Geode Capital Management LLC, Dimensional Fund Advisors LP, Duality Advisers LP and Caledonia Investments PLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $235.41.

Waters has a market capitalization of $17.83 billion and generates $2.42 billion in revenue each year. The medical instruments supplier earns $593.79 million in net income (profit) each year or $8.29 on an earnings per share basis. Waters employs 7,000 workers across the globe.

The official website for Waters is http://www.waters.com.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]